Interferon alfa 2b

Interferon alfa 2b
Clinical data
MedlinePlus a690006
Pregnancy
category
  • US: C (Risk not ruled out)
Legal status
Routes of
administration		 Subcutaneous, intramuscular
Identifiers
ATC code L03AB05
IUPHAR/BPS 8338
DrugBank DB00105 YesY
ChemSpider none
ChEMBL CHEMBL1201558 N
 NYesY (what is this?)  (verify)

Interferon alfa 2b is an antiviral drug originally discovered in the laboratory of Charles Weissmann at the University of Zurich, developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.

This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.

Interferon alfa-2b products[1]
Product Manufacturer Features Special uses
Alpharona Pharmaclon
Intron-A/IntronA Schering-Plough
Realderon Teva
Reaferon EC GNC Vector
Reaferon EC-Lipint Vector-Medica liposomal
Infagel Vector-Medica ointment
Recolin Vector-Medica
Altevir Bioprocess subsidiary liquid, free of HSA
Kipferon Alfarm combination with IgM, IgA, IgG
Giaferon A/S Vitafarma
Genferon Biocad
Opthalamoferon Firn-M with dimedrol eye infections

See also

References

  1. ↑ Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J 2.

External links


This article is issued from Wikipedia - version of the Friday, December 11, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.